Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Navidea Biopharmaceuticals Inc announces data demonstrating Potential of Manocept Platform to Diagnose Rheumatoid Arthritis and Kaposi's Sarcoma


Tuesday, 10 Jun 2014 08:00am EDT 

Navidea Biopharmaceuticals Inc:Results from three research studies performed with collaborators that demonstrate the potential for company's Manocept platform imaging agents to diagnose and stage rheumatoid arthritis (RA) and Kaposi's Sarcoma (KS).These data reinforce potential for macrophage-targeting Manocept platform, from which FDA-approved product Lymphoseek (technetium 99m tilmanocept) Injection is derived, to significantly expand commercial opportunities by addressing immuno-inflammatory disorders.Says archival synovial tissue and synovial fluid obtained from patients diagnosed with RA contain a significant population of macrophages that express high-levels of the CD206 receptor.Says it was shown that these macrophages strongly co-localize Cy3-tilmanocept and CD206 receptors.Says degree of macrophage infiltration in tissue from healthy or osteoarthritic patients was significantly lower than in RA tissues. 

Company Quote

1.81
0.02 +1.12%
10:31am EST